AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Introduction
This chapter explores the experimental drug MTX325, which inhibits the enzyme USP30 and promotes mitochondrial quality control, making it a potential therapy for Parkinson's disease. The collaborative study between Cambridge University, Harvard Medical School, and Mission Therapeutics highlights the significance of healthy mitochondrial function and the need for further research on USP30 inhibition.